Revelation Biosciences, Inc. (REVB) Stock

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company dedicated to advancing immune system therapeutics and diagnostics. Specializing in the development and commercialization of innovative treatments, the company focuses on addressing critical medical needs across various conditions.

Central to its pipeline are therapeutic candidates like REVTx-100, designed to potentially prevent and treat healthcare-associated bacterial infections arising from surgical procedures, severe burns, and antibiotic resistance. Additionally, Revelation Biosciences is developing REVTx-200, an intranasal therapy, and REVTx-300, targeting chronic organ diseases such as chronic kidney disease and non-alcoholic steatohepatitis.

Further expanding its innovative portfolio, the company is pioneering REVTx-99b for food allergies, REVTx-99a as an anti-viral nasal drop solution for respiratory viral infections, and REVDx-501, a rapid point-of-care diagnostic kit capable of detecting various respiratory viral infections including SARS-CoV-2 and influenza strains. Founded in 2020 and headquartered in San Diego, California, Revelation Biosciences remains committed to addvancing healthcare solutions that improve patient outcomes globally.